PYC Therapeutics : Corporate Presentation - May 2022

only

Life-changing

Corporate

ersonal use

science Presentation

May 2022

1

Disclaimer

The purpose of this presentation is to provide an update of the business of PYC Therapeutics Limited (ASX:PYC) ['PYC']. These onlyslides have been prepared as a presentation aid only and the information they contain may require further explanation and/or

clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future a nouncements made by PYC Therapeutics and should not be relied upon as an independent source of information. Please contact PYC and/or refer to the Company's website for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

usediffer materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and PYC's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks,

uncertainties and other factors, many of which are outside PYC's control. Important factors that could cause actual results to

This presentation should not be relied on as a recommendation or forecast by PYC. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

ersonal

2

Company Overview

ersonal use only

PYC Therapeutics:

• Designs and develops precision RNA therapies for patients with genetic diseases who currently have no treatment options available
• Overcomes the major challenge in the precision medicine field (getting enough drug to the target) through its proprietary drug delivery platform
• Is progressing multiple programs built on this platform technology into clinical development in the area with the highest prospect of success in the industry (monogenic diseases)¹

1 Refer addendum	3

PYC strives to change patient lives in markets estimated to be worth > A$1 billion p.a. each

	Organ		Program		Target	Discovery	Pre-clinical	IND enabling
only		VP-001*		PRPF31		RP11
use		PYC-001		OPA1	ADOA
	PYC-002		Undisclosed
	PYC-003		Undisclosed

Scalable platform technology

PYC 93.5% ownership of VP-001 (6.5% ownership by Lions Eye Institute, Australia) and 100% ownership of all other pipeline programs

1. r	f	r footnote slide 8
2. r	f	r footnote slide 14
rsonale

Estimated market opportunity

Clinical Trials	Marketed
	>A$1bn p.a.1
	>A$1.5bn p.a.2

4

5

Refer addendum

delivery environment

Focus on blindness

Initially targeting eye diseases due to the major unmet patient need and controlled

Rapid path to market

Targeted diseases have no current treatments available - potentially reducing the time taken in the path to market

Delivery Platform

100x more drug to the targetcurrent industry methods

via patented delivery technology compared to

focuses on monogenic diseases with high target validation

diseases

5x greater success ratein clinical trials compared to polygenic diseases1 - PYC

Monogenic

Orphan Drug

Estimated >$1bn p.a. marketfor each of the Company's programs - Target orphan (rare) diseases (patient populations < 200,000 in US)

PYC operates within a specific domain and with a clear competitive advantage

PYC's probability of successful market entry is higher than the industry average and the Company benefits

from the potential of a rapid path to market in the unmet needs it is addressing onlyuse

ersonal1